SCHEMBL18369799

SCHEMBL18369799

Cc1cc(CN2CCCC2)ccc1Nc1cc2c(cn1)N(C)C(=O)c1ccccc1N2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK7 Q13164 12/20 0.51
▸ BRD4 O60885 7/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ LRRK2 Q5S007 9/20 0.44
▸ DCLK1 O15075 8/20 0.44
▸ PIK3CD O00329 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ PIK3C2G O75747 1/20 0.44
▸ PIK3CG P48736 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ TNK2 Q07912 3/20 0.40
▸ TNK1 Q13470 2/20 0.38
▸ DCLK2 Q8N568 2/20 0.38
▸ GAK O14976 1/20 0.38
▸ NUAK1 O60285 1/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ PI4KA P42356 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.37
▸ PTK2 Q05397 1/20 0.37
▸ RPS6KA2 Q15349 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18369873 0.89 MAPK7 (0.58) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL17059908 0.86 MAPK7 (0.52) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL18369826 0.82 MAPK7 (0.54) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL18369886 0.81 MAPK7 (0.57) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL18369863 0.81 MAPK7 (0.55) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL17059912 0.80 MAPK7 (0.52) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL18369869 0.79 PRKDC (0.53) MAPK7BRD4KCNH2PIK3CDAURKA
SCHEMBL18369922 0.78 MAPK7 (0.50) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL18370064 0.77 MAPK7 (0.55) MAPK7BRD4KCNH2LRRK2DCLK1
SCHEMBL18369946 0.75 MAPK7 (0.51) MAPK7BRD4KCNH2LRRK2DCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008888-A1 HETEROCYCLIC COMPOUNDS BET1, EP300, RBBP5 MAPK7 58/4885BRD4 4/4885KCNH2 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback